<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Platelet activation results in the formation of various vasoactive mediators such as <z:chebi fb="0" ids="15627">thromboxane A2</z:chebi> and <z:chebi fb="19" ids="28790">serotonin</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>We investigated the effects of Bay U 3405 [(3R)-3- (4-fluorophenyl-sulfonamido)-1,2,3,4,-tetrahydro-9-carbazolepro panoic acid] on vasocontractions of isolated bovine cerebral arteries induced by U 46.619, a stable <z:chebi fb="0" ids="26995">thromboxane</z:chebi>/<z:chebi fb="11" ids="26333">prostaglandin</z:chebi>-endoperoxide analogue, and authentic <z:chebi fb="0" ids="15627">thromboxane A2</z:chebi> released from thrombin-stimulated human platelets </plain></SENT>
<SENT sid="2" pm="."><plain>Bay U 3405 (0.001-10 mumol/l) potently inhibited the contraction induced by U 46.619 and demonstrated a reduction of the <z:chebi fb="0" ids="26995">thromboxane</z:chebi>-mediated component of platelet-induced contractile response at higher concentrations (0.1-10 mumol) </plain></SENT>
</text></document>